U.K. reports fake Colgate toothpaste
This article was originally published in The Tan Sheet
Executive Summary
British supermarket chain Sainsbury's and drugstore chain Boots recalled counterfeit Colgate Cavity Protectiontoothpaste in 100 mL cartons, the companies say. Colgate-Palmolive says Dec. 24 that no adverse events linked to the products were reported and the counterfeits were limited to the two U.K. chains. Sainsbury's says it asked customers to return the toothpaste for a full refund and is investigating "how this has occurred so that we can prevent it from happening again." Colgate-Palmolive warned U.S. consumers in June 2007 about South Africa-made counterfeit toothpaste that may have contained diethylene glycol (1"The Tan Sheet" June 18, 2007, In Brief). The firm says tests found no evidence of DEG in the current batch of fakes
You may also be interested in...
Counterfeit Colgate
Colgate-Palmolive warns in a June 14 statement counterfeit toothpaste packaged under the Colgate brand has been found in several "dollar-type discount stores" in four states: New York, New Jersey, Pennsylvania and Maryland. "There are indications that this product does not contain fluoride and may contain diethylene glycol," the firm says. The company stressed "that it does not use, nor has ever used, DEG as an ingredient in Colgate toothpaste anywhere in the world." The counterfeit toothpaste is easily recognizable because it is labeled as "Manufactured in South Africa," the firm says, noting that it does not import toothpaste into the U.S. from South Africa. The counterfeit packages also bear several misspellings: "isclinically," "SOUTH AFRLCA" and "South African Dental Assoxiation." Colgate is working closely with FDA to help identify those responsible for the counterfeit product. Earlier this month, concern arose over DEG-containing toothpaste from China (1"The Tan Sheet" June 11, 2007, p. 8)...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.